Senolytic drugs clear harmful microglia from the aging brain

Senolytic pharmacological interventions successfully remove harmful senescent microglia from the white matter of aged brains, according to research conducted in naturally aged mice. The study identified a brain-exclusive microglial population concentrated in the fimbria—tissue adjacent to the hippocampus—that simultaneously expresses markers of disease-associated microglia (DAM) and a senescence signature, including galectin-3 (GAL3). Using spatial molecular profiling and trajectory analysis, researchers demonstrated that senotherapeutic approaches significantly reduced GAL3+ microglia and restored a more youthful microglial organization in aged white matter. This matters because senescent, proinflammatory microglia accelerate cognitive decline and neurodegeneration linked to aging; yet senolytic drugs remain largely untested in patients with neurodegenerative diseases beyond a single small Alzheimer's clinical trial. For the longevity-focused reader and researcher, these findings outline a pharmacological pathway to counteract age-related cognitive dysfunction through cellular senescence clearance.